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Abstract
Introduction
Recent in-vitro studies have suggested that a critical checkpoint early in the inflammatory
process involves the interaction between neutrophils and platelets. This confirms the
importance of the innate immune system in the elaboration of the systemic inflammatory
response. The aim of the present study was to examine whether a combination of the neu-
trophil and platelet counts were predictive of survival in patients with cancer.
Methods
Patients with histologically proven colorectal cancer who underwent potentially curative
resection at a single centre between March 1999 and May 2013 (n = 796) and patients with
cancer from the Glasgow Inflammation Outcome Study, who had a blood sample taken
between January 2000 and December 2007 (n = 9649) were included in the analysis.
Results
In the colorectal cancer cohort, there were 173 cancer and 135 non-cancer deaths. In
patients undergoing elective surgery, cancer-specific survival (CSS) at 5 years ranged from
97% in patients with TNM I disease and NPS = 0 to 57% in patients with TNM III disease
and NPS = 2 (p = 0.019) and in patients undergoing elective surgery for node-negative
colon cancer from 98% (TNM I, NPS = 0) to 65% (TNM II, NPS = 2) (p = 0.004). In those
with a variety of common cancers there were 5218 cancer and 929 non-cancer deaths. On
multivariate analysis, adjusting for age and sex and stratified by tumour site, incremental
increase in the NPS was significantly associated with poorer CSS (p<0.001).
Conclusion
The neutrophil-platelet score predicted survival in a variety of common cancers and high-
lights the importance of the innate immune system in patients with cancer.
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Introduction
Colorectal cancer is the second most common cause of cancer death in the UK [1]. In recent
decades, mortality rates have been falling and the introduction of bowel screening in many
parts of the UK is likely to reduce this further. Despite this, approximately 40% of patients will
ultimately die from their disease [2]. In patients with colorectal cancer, surgery remains the
main method of cure.
It is now established that the presence of a pre-operative systemic inflammatory response is
predictive of disease progression and poorer outcome, regardless of tumour stage, in patients
with colorectal cancer [3]. Indeed, systemic inflammation based scoring systems such as the
modified Glasgow Prognostic Score (mGPS) and the Neutrophil-Lymphocyte ratio (NLR)
have prognostic value in a range of common solid tumours [4–9]. However, with reference to
the NLR, multiple thresholds have been used to define high and low NLR values and some
have suggested that its prognostic value is mainly derived from the neutrophil count and that
the lymphocyte count makes little contribution [10].
Therefore, it is of interest that recent in-vitro studies have suggested that a critical check-
point early in the inflammatory process involves the interaction between neutrophils and plate-
lets [11]. During this process, neutrophils that are recruited to injured tissues/vessels, scan for
activated platelets and when detected neutrophils undergo intravascular migration, further
elaborating the inflammatory process. This in-vitro research highlights the importance of the
innate immune system, in particular neutrophils, in the elaboration of the systemic inflamma-
tory response. If the interaction between neutrophils and platelets were of clinical relevance
then it might be expected that an elevated neutrophil count in the presence of an elevated plate-
let count would result in an enhanced systemic inflammatory response. Indeed the combina-
tion of a platelet count and the NLR (COP-NLR) has recently been reported as a cumulative
predictor of survival in patients with colorectal [12], gastric [13] and oesophageal cancer [14].
However, given that the lymphocyte count makes little contribution to the prognostic value of
the NLR [10, 15], it could be hypothesised that a combination of the neutrophil and platelet
counts could have considerable prognostic value in predicting survival in patients with cancer.
Therefore, the aim of the present study was to examine whether a combination of the neutro-
phil count and the platelet count was predictive of survival in patients undergoing potentially
curative surgery for colorectal cancer and in patients with a variety of common cancers.
Materials and Methods
For the colorectal cancer cohort, patients with histologically proven colorectal cancer who, on
the basis of intra-operative findings and pre-operative computed tomography, were considered
to have undergone potentially curative resection at a single centre between March 1999 and
May 2013 (n = 813) were initially selected for analysis. Patients in whom a pre-operative neu-
trophil or platelet count were not available were excluded from analysis (n = 6) as were those
patients with TNM stage 0 disease (n = 11). Patient characteristics were collected in a prospec-
tively maintained database and all patient data was anonymised. All tumours were staged
according to conventional tumour, node, metastasis classification and additional pathological
data obtained from the pathology reports issued at the time of the resection.
Pre-operatively, all patients received thromboembolism prophylaxis and antibiotic prophy-
laxis as per local protocols and blood samples were taken for routine laboratory analysis.
Cut-off values for both neutrophil and platelet count were based on previously reported val-
ues [10, 16]. The neutrophil-platelet score (NPS) was calculated as follows Table 1: patients
with a neutrophil count7.5 x109/L and platelets400 x109/L scored 0, patients with
NPS Predicts Survival in Common Cancers
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neutrophils>7.5 x109/L or platelets>400 x109/L scored 1 and patients with both
neutrophils>7.5 x109/L and platelets>400 x109/L scored 2.
Patients were routinely followed up for 5 years following resection as per national guide-
lines. Date and cause of death were crosschecked with the cancer registration system and Regis-
trar General (Scotland). Cancer specific survival was measured from date of surgery until date
of death. This was an observational study involving patients who underwent surgery for colo-
rectal cancer and their clinical data. As such no specific consent, either written or verbal was
obtained to use this data. This was approved by the West of Scotland Research Ethics Commit-
tee, Glasgow.
For the larger, common cancer cohort, data was taken from the Glasgow Inflammation Out-
come Study [17]. Patients with routine laboratory measurements of C-reactive protein, albu-
min and a differential white cell count sampled between January 2000 and December 2007,
including neutrophil and platelet counts were obtained by systematically searching the North
Glasgow biochemical and haematological database systems. Of the 160,481 patients identified,
through linkage with the Scottish Cancer Registry using exact matches of the patient’s fore-
name, surname and date of birth, 27 465 were found to have an associated diagnosis of cancer.
Of those that had common cancers previously studied in the GIOS cohort, 9649 had been sam-
pled within two years of their cancer diagnosis and were included in the analysis. Cancers were
coded according to the International Classification of Disease 10 (ICD-10) and broadly
grouped according to the tumour site. Tumours were listed in order of the magnitude of their
inflammatory status as previously demonstrated [18]. Patient mortality was established
through linkage with the Information Service Division for Scotland (ISD). Patients were
excluded if they did not have a blood sample within 2 years of their cancer diagnosis, had
incomplete cancer registry follow up, under 16 years old, did not have a complete set of blood
results available, had multiple tumours or metastatic disease or had a primary tumour of
unknown origin.
Statistical analysis
The comparison of clinicopathological variables across different NPS scores was performed
using a Chi square test. The relationship between the NPS and 5-year survival was examined
using log-rank survival analysis. Kaplan-Meier analysis was used to examine the relationship
between patients characteristics, NPS, tumour site and cancer-specific and overall survival.
Cox proportional hazards multivariate regression models (stratified by tumour site) were used
to correct for age and sex and examine the relationship between patient characteristics, NPS
and survival. A two-sided p-value of< 0.05 was considered statistically significant. Analyses
were performed using SPSS 22.0 (IBM, SPSS, IL, USA).
Results
A total of 796 patients were included in the analysis of patients undergoing potentially curative
surgery for colorectal cancer. The majority were over the age of 65 (66%), male (55%), under-
went elective surgery (90%), had an open procedure (87%) and had node negative disease
Table 1. The neutrophil platelet score (NPS).
Score Thresholds
NPS 0 Neutrophils  7.5 x109/L and Platelets 400 x109/L
NPS 1 Neutrophils >7.5 x109/L or Platelets >400 x109/L
NPS 2 Neutrophils >7.5 x109/L and Platelets >400 x109/L
doi:10.1371/journal.pone.0142159.t001
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(61%). Median follow up of survivors was 49 (10–180) months with 173 cancer deaths and 135
non-cancer deaths. Table 2 shows the distribution of the clinicopathological characteristics
based on the NPS score. Mode of presentation, tumour site, T-stage, TNM stage, margin
involvement, peritoneal involvement, tumour perforation and mGPS were significantly differ-
ent between the 3 NPS groups. On multivariate analysis, adjusting for age and sex and stratified
by TNM stage, incremental increase in the NPS was associated with poorer cancer-specific
(NPS 1 –HR 1.37, p = 0.091; NPS 2 –HR 1.61, p 0.082) and overall survival (NPS 1 –HR 1.48,
p = 0.005; NPS 2 –HR 1.51, p 0.056).
Tables 3 and 4 show the relationship between pre-operative NPS, TNM stage and 5 year
cancer-specific (CSS) and overall survival (OS). CSS in the whole cohort at 5 years varied
from 97% in patients with stage I colorectal cancer to 62% in those with stage III colorectal can-
cer (p< 0.001) and from 79% in patients with NPS = 0 to 65% in patients with NPS = 2
(p = 0.001). When combined, 5 year CSS varied from 97% in patients with stage I disease and
NPS = 0, to 60% in patients with stage III disease and NPS = 2 (p = 0.026). OS at 5 years ranged
from 86% in patients with stage I disease to 52% in patients with stage III disease (p< 0.001)
and from 68% in patients with NPS = 0 to 48% in patients with NPS = 2 (p< 0.001). When
combined, OS at 5 years ranged from 89% in patients with stage I disease and NPS = 0 to 49%
in patients with stage III disease and NPS = 2 (p = 0.001).
The combination of the platelet count and NLR (COP-NLR) was calculated (using an NLR
threshold of 5) in order to determine its effect on survival in patients with operable colorectal
cancer. CSS in the whole cohort at 5 years ranged from 78% in patients with COP-NLR = 0 to
67% in patients with COP-NLR = 2 (p = 0.010). Furthermore, on multivariate analysis, adjust-
ing for age and sex and stratified by TNM stage, incremental increase in the COP-NLR was not
independently associated with cancer-specific survival (COP-NLR 1 –HR 1.31, p = 0.112;
COP-NLR 2 –HR 1.41, p 0.268). Therefore, in comparison to COP-NLR, the NPS was superior
in predicting survival in patients with operable colorectal cancer.
As emergency surgery, presence of a colonic tumour and nodal status were associated with
the NPS, to control for confounding of these, 5 year survival (both CSS and OS) was examined
in patients undergoing elective surgery and then in patients with node negative disease and
node negative colonic disease Tables 3 and 4.
In patients undergoing elective surgery, CSS at 5 years ranged from 97% in stage I disease to
63% in stage III disease (p< 0.001) and from 80% in patients with NPS = 0 to 62% in patients
with NPS = 2 (p = 0.001). When combined, CSS at 5 years ranged from 97% in patients with
stage I disease and NPS = 0 to 57% in patients with stage III disease and NPS = 2 (p = 0.019). A
similar relationship was observed in OS at 5 years as survival ranged from 86% to 52%
(p< 0.001) and from 69% to 41% (p< 0.001) with TNM stage and NPS alone, the combina-
tion of TMN stage and NPS stratified OS from 89% (TNM I, NPS = 0) to 42% (TNM III,
NPS = 2) (p< 0.001).
In patients undergoing elective surgery for node negative disease, CSS at 5 years ranged
from 97% in stage I disease to 83% in stage II disease (p = 0.003) and from 89% in patients with
NPS = 0 to 71% in patients with NPS = 2 (p = 0.002). When combined CSS ranged from 97%
(TNM stage I, NPS = 0) to 68% (TNM stage II, NPS = 2) (p = 0.018). Similarly, OS at 5 years
ranged from 86% to 71% (p = 0.012) and from 78% to 42% (p< 0.001) with TNM stage and
NPS alone and the combination of TNM stage and NPS stratified OS from 89% (TNM I,
NPS = 0) to 37% (TNM II, NPS = 0) (p< 0.001).
In patients undergoing elective surgery for node negative colonic disease CSS at 5 years ran-
ged from 99% in stage I disease to 77% in stage II disease (p = 0.003) and from 91% in patients
with NPS = 0 to 65% in patients with NPS = 2 (p< 0.001). When combined, CSS ranged from
98% (TNM stage I, NPS = 0) to 65% (TNM stage II, NPS = 2) (p = 0.004). Similarly, OS at
NPS Predicts Survival in Common Cancers
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Table 2. The relationship between neutrophil platelet score (NPS) and clinicopathological characteristics in patients undergoing potentially cura-
tive resection of colorectal cancer.
All NPS = 0 NPS = 1 NPS = 2 p-value
ClinicopathologicalCharacteristic n = 796(%) n = 621(%) n = 133(%) n = 42(%)
Age 0.318
<65 266 (34) 210 (34) 42 (32) 14 (33)
65–74 272 (34) 221 (36) 39 (29) 12 (29)
>75 258 (32) 190 (30) 52 (39) 16 (38)
Sex 0.553
Female 361 (45) 276 (44) 66 (50) 27 (64)
Male 435 (55) 345 (56) 67 (50) 23 (55)
Presentation <0.001
Elective 718 (90) 582 (94) 109 (82) 27 (64)
Emergency 78 (10) 39 (6) 24 (18) 15 (36)
Adjuvant Therapy 0.241
No 585 (74) 464 (75) 94 (71) 27 (64)
Yes 211 (26) 157 (25) 39 (29) 15 (36)
Tumour Site <0.001
Colon 525 (66) 385 (62) 103 (77) 37 (88)
Rectum 271 (34) 236 (38) 30 (23) 5 (12)
T-stage <0.001
1 58 (7) 54 (9) 4 (3) 0 (0)
2 102 (13) 94 (15) 7 (5) 1 (2)
3 432 (54) 338 (54) 74 (56) 20 (48)
4 204 (26) 135 (22) 48 (36) 21 (50)
N-stage 0.068
0 486 (61) 391 (63) 71 (53) 24 (57)
1 224 (28) 172 (28) 42 (32) 10 (24)
2 86 (11) 58 (9) 20 (15) 8 (19)
TNM Stage <0.001
1 132 (17) 124 (20) 7 (5) 1 (2)
2 354 (44) 267 (43) 64 (48) 23 (55)
3 310 (39) 230 (37) 62 (47) 18 (43)
Differentiation 0.225
Mod/well 710 (90) 560 (91) 113 (86) 37 (88)
Poor 78 (10) 55 (9) 18 (14) 5 (12)
Venous invasion 0.309
No 354 (45) 285 (46) 53 (40) 16 (38)
Yes 442 (55) 336 (54) 80 (60) 26 (62)
Margin Involvement <0.001
No 738 (93) 590 (95) 110 (83) 38 (91)
Yes 58 (7) 31 (5) 23 (17) 4 (9)
Peritoneal Involvement 0.001
No 617 (78) 499 (80) 93 (70) 25 (60)
Yes 179 (22) 122 (20) 40 (30) 17 (40)
Tumour perforation <0.001
No 776 (98) 612 (99) 127 (96) 37 (88)
Yes 20 (2) 9 (1) 6 (4) 5 (12)
Modiﬁed Glasgow Prognostic Score (mGPS) <0.001
0 505 (63) 450 (73) 46 (35) 9 (21)
(Continued)
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5 years ranged from 83% to 72% (p = 0.039) and from 78% to 46% (p< 0.001) with TNM stage
and NPS alone, the combination of TNM stage and NPS stratified OS from 56% (TNM stage I,
NPS = 0) to 46% (TNM stage II, NPS = 2) (p = 0.002).
The relationship between the clinicopathological characteristics and the NPS score in
patients with a range of common cancers are in shown in Table 5. Age, sex, mode of
Table 2. (Continued)
All NPS = 0 NPS = 1 NPS = 2 p-value
ClinicopathologicalCharacteristic n = 796(%) n = 621(%) n = 133(%) n = 42(%)
1 164 (21) 102 (16) 45 (34) 17 (41)
2 127 (16) 69 (11) 42 (31) 16 (38)
Survival Status <0.001
Alive 488 (61) 407 (66) 64 (48) 17 (40)
Cancer death 173 (22) 120 (19) 38 (29) 15 (36)
Non-cancer death 135 (17) 94 (15) 31 (23) 10 (24)
Survival (Months)$ 103 107 69 57 <0.001
$ median overall survival
doi:10.1371/journal.pone.0142159.t002
Table 3. The relationship between neutrophil platelet score (NPS) and 5 year cancer-specific survival
in patients undergoing curative resection of colorectal cancer. CSS—cancer-specific survival. Survival
not calculated if n<10.
NPS = 0
(Neut  7.5 x109/
L and Plat 400
x109/L)
NPS = 1(Neut
>7.5 x109/L or
Plat >400 x109/L)
NPS = 2(Neut
>7.5 x109/L and
Plat >400 x109/
L)
All(NPS 0–2)
All Patients n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
Stage I 124 97 (2) 7 - 1 - 132 97 (2)
Stage II 267 85 (3) 64 79 (6) 23 68 (11) 354 82 (2)
Stage III 230 63 (4) 62 56 (7) 18 60 (12) 310 62 (3)
All (Stage 0-III) 621 79 (2) 133 69 (5) 42 65 (8) 796 76 (2)
Elective n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
Stage I 124 97 (2) 7 - 1 - 132 97 (2)
Stage II 248 85 (3) 53 79 (6) 14 68 (13) 315 83 (2)
Stage III 210 65 (4) 49 58 (8) 12 57 (15) 271 63 (3)
All (Stage 0-III) 582 80 (2) 109 70 (5) 27 62 (10) 718 78 (2)
Elective, Node
Negative
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
Stage I 124 97 (2) 7 - 1 - 132 97 (2)
Stage II 248 85 (3) 53 79 (6) 14 68 (13) 315 83 (2)
All (Stage 0-II) 372 89 (2) 60 81 (6) 15 71 (12) 447 87 (2)
Elective, Node
Negative Colon
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
n 5-yr CSS %
(SE)
Stage I 71 98 (2) 6 - 0 - 77 99 (1)
Stage II 161 89 (3) 40 82 (7) 12 65 (14) 213 77 (4)
All (Stage 0-II) 232 91 (2) 46 84 (6) 12 65 (14) 290 89 (2)
doi:10.1371/journal.pone.0142159.t003
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presentation, tumour site, mGPS, survival status and survival length were significantly different
between NPS groups. On multivariate analysis, adjusting for age and sex and stratified by
tumour site, incremental increase in the NPS was significantly associated with poorer cancer-
specific (NPS 1 –HR 1.60, p< 0.001; NPS 2 –HR 2.14, p< 0.001) and overall survival (NPS 1 –
HR 1.61, p< 0.001; NPS 2 –HR 2.19, p< 0.001).
On Kaplan Meier survival analysis, a greater neutrophil-platelet score is associated with
poorer cancer-specific survival in all patients (p< 0.001) Fig 1. On Kaplan Meier survival anal-
ysis, based on individual tumour types Fig 2, increasing NPS was significantly associated with
poorer cancer-specific survival in patients with breast (p< 0.001), bladder (p< 0.001), colo-
rectal (p< 0.001), gastroeosophageal (p< 0.001), gynaecological (p< 0.001), head and neck
(p< 0.001), Hepaticopancreaticobiliary (HPB) (p = 0.009), prostatic (p< 0.001), pulmonary
(p< 0.001) and renal cancers (p< 0.001).
Discussion
The results of the present study show that the combination of neutrophils and platelets in a
clinical scoring system, the neutrophil-platelet score (NPS), can be used to predict survival,
independent of TNM stage, in patients undergoing potentially curative surgery for colorectal
cancer. Furthermore, the results of the present study provide evidence that this simple, novel,
objective score has prognostic value in a variety of common cancers. These results confirm the
Table 4. The relationship between neutrophil platelet score (NPS) and 5 year overall survival in
patients undergoing potentially curative resection of colorectal cancer. OS—overall survival. Survival
not calculated if n<10.
NPS = 0
(Neut  7.5 x109/
L and Plat 400
x109/L)
NPS = 1(Neut
>7.5 x109/L or
Plat >400 x109/L)
NPS = 2(Neut
>7.5 x109/L and
Plat >400 x109/
L)
All(NPS 0–2)
All Patients n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
Stage I 124 89 (4) 7 - 1 - 132 86 (4)
Stage II 267 73 (3) 64 68 (6) 23 45 (11) 354 70 (3)
Stage III 230 54 (4) 62 45 (7) 18 49 (12) 310 52 (3)
All (Stage 0-III) 621 68 (2) 133 56 (5) 42 48 (8) 796 65 (2)
Elective n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
Stage I 124 89 (4) 7 - 1 - 132 86 (4)
Stage II 248 74 (3) 53 68 (7) 14 37 (14) 315 71 (3)
Stage III 210 55 (4) 49 45 (8) 12 42 (14) 271 52 (3)
All (Stage 0-III) 582 69 (2) 109 56 (5) 27 41 (10) 718 66 (2)
Elective, Node
Negative
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
Stage I 124 89 (4) 7 - 1 - 132 86 (4)
Stage II 248 74 (3) 53 68 (7) 14 37 (14) 315 71 (3)
All (Stage 0-II) 372 78 (3) 60 65 (7) 15 42 (14) 447 75 (2)
Elective, Node
Negative Colon
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
n 5-yr OS %
(SE)
Stage I 71 56 (12) 6 - 0 - 77 83 (5)
Stage II 161 75 (4) 40 25 (10) 12 46 (15) 213 72 (4)
All (Stage 0-II) 232 78 (3) 46 24 (9) 12 46 (15) 290 75 (3)
doi:10.1371/journal.pone.0142159.t004
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importance of activation of the innate immune response in predicting outcome in patients
with cancer.
The results of the present study are consistent with those of Ishizuka and colleagues who
reported that the combination of platelets and the NLR was a predictor of post-operative sur-
vival in both colorectal and gastric cancer [12, 13]. However, recent evidence would appear to
suggest that when using the differential white cell count to predict outcomes, the neutrophil
count is the dominant component and as a result the lymphocyte count adds little to its prog-
nostic effect [10]. Furthermore, recent work [12, 13] has suggested that the combination of a
platelet count to the NLR (COP-NLR) improves the prediction of outcome. In the present
study when the prognostic value of the COP-NLR was examined, the NPS had superior
Table 5. The relationship between neutrophil platelet score (NPS) and patient demographics in an incidentally sampled cohort of patients with
cancer.
All NPS = 0 NPS = 1 NPS = 2 p-value
n = 9649(%) n = 5933(%) n = 2779(%) n = 937(%)
Age <0.001
<65 4631 (48) 3032 (51) 1170 (42) 429 (46)
65–74 2885 (30) 1696 (29) 886 (32) 303 (32)
>75 2133 (22) 1205 (20) 723 (26) 205 (22)
Sex <0.001
Female 4584 (48) 2646 (45) 1468 (53) 470 (50)
Male 5065 (52) 3287 (55) 1311 (47) 467 (50)
Presentation <0001
Non-Emergency 6098 (63) 4236 (71) 1398 (50) 464 (50)
Emergency 3551 (37) 1697 (29) 1381 (50) 473 (50)
Tumour Site <0.001
Breast 1921 (20) 1611 (27) 268 (10) 42 (5)
Bladder 437 (4) 259 (4) 128 (5) 50 (5)
Gynaecological 507 (5) 298 (5) 142 (5) 67 (7)
Prostatic 509 (5) 322 (6) 159 (6) 28 (3)
Gastroesophageal 933 (10) 548 (9) 294 (10) 91 (10)
Haematological 914 (9) 678 (12) 188 (7) 48 (5)
Renal 459 (5) 288 (5) 134 (5) 37 (4)
Colorectal 1086 (11) 604 (10) 356 (13) 126 (13)
Head And Neck 633 (7) 365 (6) 204 (7) 64 (7)
Hepaticopancreaticobiliary 556 (6) 309 (5) 183 (6) 64 (7)
Pulmonary 1694 (18) 651 (11) 723 (26) 320 (34)
mGPS <0.001
0 4013 (42) 3305 (56) 629 (23) 79 (9)
1 2757 (28) 1504 (25) 931 (33) 322 (34)
2 2879 (30) 1124 (19) 1219 (44) 536 (57)
Survival Status <0.001
Alive 3502 (36) 2757 (47) 633 (23) 112 (12)
Cancer death 5218 (54) 2620 (44) 1849 (66) 749 (80)
Non-cancer death 929 (10) 556 (9) 297 (11) 76 (8)
Survival (Months)$ 21 55 7 3 <0.001
$ median overall survival
doi:10.1371/journal.pone.0142159.t005
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prognostic value. Due to the differences in the formation of the COP-NLR and the NPS the
basis of the difference in prognostic value is not clear. Nevertheless, taken together these results
would suggest that neutrophils and platelets were the main factors determining the prognostic
value of the COP-NLR.
There are other systemic inflammation based scores that have prognostic value in patients
with primary operable colorectal cancer and a variety of common solid tumours. The most val-
idated of these is the GPS/mGPS [5, 8, 17]. Indeed, it was of interest in the present study that as
the NPS increased from 0 to 2 the median concentration of CRP increased from 6 to 55 mg/L
and median concentration of albumin decreased from 38 to 36 g/L (both p< 0.001). Therefore
it would appear that both these scoring systems are related measures of the systemic inflamma-
tory response. Nevertheless, the present results are of considerable interest since the GPS/
mGPS requires the measurement of two acute phase proteins and in many centres they may
not be routinely assessed. Together with previous results [19] the present results show the com-
plementary prognostic value of the NPS.
It is of interest that Kumar and colleagues recently reported that, in 1300 patients in phase I
clinical cancer trials, the neutrophil-lymphocyte ratio (NLR) was an independent prognostic
factor for overall survival [15]. Furthermore, they reported that the neutrophil count but not
Fig 1. The relationship between the NPS and cancer specific survival in all patients of the GIOS cohort. NPS 0 (top, small dash line), NPS 1 (middle,
large dash line) and NPS 2 (bottom, solid line) (p<0.001).
doi:10.1371/journal.pone.0142159.g001
NPS Predicts Survival in Common Cancers
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the lymphocyte count had prognostic value. This finding is consistent with our work in
patients with primary operable colorectal cancer [10, 16]. The results of the present study dem-
onstrate that the combination of increased neutrophils and platelets (both components of the
innate immune response) was associated with an elaboration of the systemic inflammatory
response and significantly poorer survival in patient with a range of common cancers. Taken
together, these findings suggest that activation of the innate immune response is a key step in
disease progression and poor survival in patients with cancer.
The elaboration of this systemic inflammatory response and the presence of high numbers
of neutrophils and platelets may result in an enhancement of cellular breakdown and prolifera-
tion (tissue remodelling). Specifically, neutrophils contain multiple enzymes such as, myelo-
peroxidase, interleukin-6 (IL-6), defensins, lysozyme and collagenase which may directly
promote cancer cell intravasation and extravasation [20, 21]. Moreover, activated platelets con-
tain significant quantities of IL-6 and secrete factors such as vascular-endothelial growth factor
(VEGF) and other factors that promote angiogenesis and may prevent recognition of cancer
cells by the body’s own immune system [22–24]. Furthermore, both neutrophils and platelets
are stimulated by IL-6. This may tip the tumour microenvironment towards disease dissemina-
tion and promotion of the growth of metastatic disease.
Fig 2. The relationship between the NPS and cancer specific survival in each tumour site. NPS 0 (top, small dash line), NPS 1 (middle, large dash line)
and NPS 2 (bottom, solid line).Breast p<0.001, bladder <0.001, gynaecological <0.001, prostatic <0.001, gastroesophageal <0.001, renal <0.001, colorectal
<0.001, head and neck <0.001, HPB = 0.009 and pulmonary <0.001.
doi:10.1371/journal.pone.0142159.g002
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The present study has a number of possible limitations. Detailed data on the use of pre-
operative chemo/radiotherapy in the colorectal cancer cohort and its relation to the timing of
the pre-operative blood samples was not available. In both cohorts, data relating to other fac-
tors that may have affected neutrophil or platelet levels such as drugs and other co-morbidities
were not available.
In conclusion, the neutrophil-platelet score can predict survival in patients undergoing
potentially curative surgery for colorectal cancer and in a variety of common cancers. This con-
firms the importance of activation of the innate immune system in patients with cancer.
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